Sippican Capital Advisors Sells 46,929 Shares of Pfizer Inc. (NYSE:PFE)

Sippican Capital Advisors lessened its stake in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 53.1% during the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 41,397 shares of the biopharmaceutical company's stock after selling 46,929 shares during the period. Sippican Capital Advisors' holdings in Pfizer were worth $1,098,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also bought and sold shares of the company. Retirement Wealth Solutions LLC bought a new position in shares of Pfizer during the fourth quarter worth approximately $26,000. Gladius Capital Management LP increased its stake in shares of Pfizer by 102.8% during the third quarter. Gladius Capital Management LP now owns 1,043 shares of the biopharmaceutical company's stock worth $30,000 after purchasing an additional 38,015 shares during the period. Quarry LP bought a new position in Pfizer during the 2nd quarter worth $31,000. Teachers Insurance & Annuity Association of America bought a new position in Pfizer during the 3rd quarter worth $35,000. Finally, Joseph Group Capital Management increased its stake in Pfizer by 168.3% during the 3rd quarter. Joseph Group Capital Management now owns 1,229 shares of the biopharmaceutical company's stock worth $36,000 after acquiring an additional 771 shares during the period. Institutional investors own 68.36% of the company's stock.

Pfizer Trading Up 1.0 %

PFE traded up $0.27 during midday trading on Thursday, hitting $26.89. 32,270,209 shares of the company were exchanged, compared to its average volume of 35,838,855. The firm has a market capitalization of $152.41 billion, a P/E ratio of 36.34, a P/E/G ratio of 0.64 and a beta of 0.64. Pfizer Inc. has a 1-year low of $24.48 and a 1-year high of $31.54. The firm's 50 day moving average price is $26.22 and its 200-day moving average price is $27.90. The company has a quick ratio of 0.73, a current ratio of 1.00 and a debt-to-equity ratio of 0.63.

Pfizer (NYSE:PFE - Get Free Report) last announced its earnings results on Tuesday, October 29th. The biopharmaceutical company reported $1.06 EPS for the quarter, topping the consensus estimate of $0.64 by $0.42. The firm had revenue of $17.70 billion for the quarter, compared to the consensus estimate of $14.92 billion. Pfizer had a return on equity of 16.28% and a net margin of 7.07%. The business's quarterly revenue was up 31.2% compared to the same quarter last year. During the same period in the previous year, the business earned ($0.17) EPS. As a group, equities analysts forecast that Pfizer Inc. will post 2.94 EPS for the current fiscal year.

Pfizer Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, March 7th. Shareholders of record on Friday, January 24th will be issued a dividend of $0.43 per share. The ex-dividend date is Friday, January 24th. This is an increase from Pfizer's previous quarterly dividend of $0.42. This represents a $1.72 annualized dividend and a yield of 6.40%. Pfizer's payout ratio is presently 227.03%.

Analyst Upgrades and Downgrades

A number of research firms have commented on PFE. Citigroup lowered their price objective on Pfizer from $30.00 to $29.00 and set a "neutral" rating on the stock in a research note on Tuesday. Guggenheim lowered their price objective on Pfizer from $35.00 to $33.00 and set a "buy" rating on the stock in a research note on Wednesday, December 11th. Cantor Fitzgerald reiterated an "overweight" rating and issued a $45.00 price target on shares of Pfizer in a research note on Wednesday, October 23rd. UBS Group decreased their price target on Pfizer from $31.00 to $29.00 and set a "neutral" rating on the stock in a research note on Wednesday, January 8th. Finally, Sanford C. Bernstein began coverage on Pfizer in a research note on Thursday, October 17th. They issued a "market perform" rating and a $32.00 price target on the stock. One equities research analyst has rated the stock with a sell rating, eight have assigned a hold rating, six have assigned a buy rating and two have given a strong buy rating to the company's stock. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average target price of $31.92.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.